dostęp otwarty

Tom 2, Nr 5 (2017)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2018-01-30
Pobierz cytowanie

Standardy Polskiego Towarzystwa Ginekologów i Położników postępowania u kobiet z cukrzycą

Ewa Wender-Ożegowska, Dorota Bomba-Opoń, Jacek Brązert, Zbigniew Celewicz, Krzysztof Czajkowski, Paweł Gutaj, Aneta Malinowska-Polubiec, Agnieszka Zawiejska, Mirosław Wielgoś
Ginekologia i Perinatologia Praktyczna 2017;2(5):215-229.

dostęp otwarty

Tom 2, Nr 5 (2017)
Opublikowany online: 2018-01-30




Pobierz cytowanie
Informacje o artykule

Standardy Polskiego Towarzystwa Ginekologów i Położników postępowania u kobiet z cukrzycą


Ginekologia i Perinatologia Praktyczna


Tom 2, Nr 5 (2017)

Typ artykułu

Wytyczne / stanowisko ekspertów



Data publikacji on-line


Rekord bibliograficzny

Ginekologia i Perinatologia Praktyczna 2017;2(5):215-229.


Ewa Wender-Ożegowska
Dorota Bomba-Opoń
Jacek Brązert
Zbigniew Celewicz
Krzysztof Czajkowski
Paweł Gutaj
Aneta Malinowska-Polubiec
Agnieszka Zawiejska
Mirosław Wielgoś

Referencje (63)
  1. Eades CE, Cameron DM, Evans JMM. Prevalence of gestational diabetes mellitus in Europe: A meta-analysis. Diabetes Res Clin Pract. 2017; 129: 173–181.
  2. Coton SJ, Nazareth I, Petersen I. A cohort study of trends in the prevalence of pregestational diabetes in pregnancy recorded in UK general practice between 1995 and 2012. BMJ Open. 2016; 6(1): e009494.
  3. Hod M, Kapur A, Sacks D, et al. The International Federation of Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes mellitus: A pragmatic guide for diagnosis, management, and care#. International Journal of Gynecology & Obstetrics. 2015; 131: S173.
  4. Charron-Prochownik D, Sereika SM, Becker D, et al. Long-term effects of the booster-enhanced READY-Girls preconception counseling program on intentions and behaviors for family planning in teens with diabetes. Diabetes Care. 2013; 36(12): 3870–3874.
  5. Peterson C, Grosse SD, Li R, et al. Preventable health and cost burden of adverse birth outcomes associated with pregestational diabetes in the United States. Am J Obstet Gynecol. 2015; 212(1): 74.e1–74.e9.
  6. Hemachandra A, Ellis D, Lloyd CE, et al. The influence of pregnancy on IDDM complications. Diabetes Care. 1995; 18(7): 950–954.
  7. Kaaja R, Sjöberg L, Hellsted T, et al. Long-term effects of pregnancy on diabetic complications. Diabet Med. 1996; 13(2): 165–169.
  8. Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care. 2000; 23(8): 1084–1091.
  9. Vérier-Mine O, Chaturvedi N, Webb D, et al. Is pregnancy a risk factor for microvascular complications? The EURODIAB Prospective Complications Study. Diabet Med. 2005; 22(11): 1503–1509.
  10. Robinson A, Nwolise C, Shawe J. Contraception for women with diabetes: challenges and solutions. Open Access Journal of Contraception. 2016: 11.
  11. Medical eligibility criteria for contraceptive use. PharmacoEconomics & Outcomes News. 2013; 312(1): 3–3.
  12. Guerin A, Nisenbaum R, Ray JG. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes. Diabetes Care. 2007; 30(7): 1920–1925.
  13. Jensen DM, Korsholm L, Ovesen P, et al. Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. Diabetes Care. 2009; 32(6): 1046–1048.
  14. Egan AM, McVicker L, Heerey A, et al. Diabetic retinopathy in pregnancy: a population-based study of women with pregestational diabetes. J Diabetes Res. 2015; 2015: 310239.
  15. Chew EY, Mills JL, Metzger BE, et al. Metabolic control and progression of retinopathy. The Diabetes in Early Pregnancy Study. National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study. Diabetes Care. 1995; 18(5): 631–637.
  16. Piccoli GB, Tavassoli E, Melluzza C, et al. Severe diabetic nephropathy in type 1 diabetes and pregnancy--a case series. Rev Diabet Stud. 2013; 10(1): 68–78.
  17. Khoury JC, Miodovnik M, LeMasters G, et al. Pregnancy outcome and progression of diabetic nephropathy. What's next? J Matern Fetal Neonatal Med. 2002; 11(4): 238–244.
  18. Mathiesen ER, Ringholm L, Feldt-Rasmussen Bo, et al. Obstetric nephrology: pregnancy in women with diabetic nephropathy--the role of antihypertensive treatment. Clin J Am Soc Nephrol. 2012; 7(12): 2081–2088.
  19. PTD Z. 2017 Guidelines on the management of diabetic patients. A position of Diabetes Poland. ; 2017: 1–80.
  20. Kitzmiller JL, Block JM, Brown FM, et al. Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care. 2008; 31(5): 1060–1079.
  21. Wytyczne ESC dotyczące postępowania w chorobach sercowo-naczyniowych u kobiet w ciąży Kardiologia Polska. 2011; 69: 341–400.
  22. Sowiński J, Czupryniak L, Milewicz A, et al. Polish Society of Endocrinology, Polish Diabetes Association. Recommendations of the Polish Society of Endocrinology and Polish Diabetes Association for the management of thyroid dysfunction in type 1 and type 2 diabetes. Endokrynol Pol. 2013; 64(1): 73–77.
  23. Hubalewska-Dydejczyk A, Lewiński A, Milewicz A, et al. [Management of thyroid diseases during pregnancy]. Endokrynol Pol. 2011; 62(4): 362–381.
  24. Bomba-Opoń D, Hirnle L, Kalinka J, et al. Folate supplementation during the preconception period, pregnancy and puerperium. Polish Society of Gynecologists and Obstetricians Guidelines. Ginekol Pol. 2017; 88(11): 633–636.
  25. Płudowski P, Karczmarewicz E, Bayer M, et al. Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe - recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency. Endokrynol Pol. 2013; 64(4): 319–327.
  26. Bullo M, Tschumi S, Bucher BS, et al. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension. 2012; 60(2): 444–450.
  27. Taguchi N, Rubin ET, Hosokawa A, et al. Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol. 2008; 26(2): 175–177.
  28. Bateman BT, Hernandez-Diaz S, Fischer MA, et al. Statins and congenital malformations: cohort study. BMJ. 2015; 350: h1035.
  29. Kitzmiller JL, Buchanan TA, Kjos S, et al. Pre-conception care of diabetes, congenital malformations, and spontaneous abortions. Diabetes Care. 1996; 19(5): 514–541.
  30. Ray JG, O'Brien TE, Chan WS. Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis. QJM. 2001; 94(8): 435–444.
  31. Parretti E, Mecacci F, Papini M, et al. Third-trimester maternal glucose levels from diurnal profiles in nondiabetic pregnancies: correlation with sonographic parameters of fetal growth. Diabetes Care. 2001; 24(8): 1319–1323.
  32. Mosca A, Paleari R, Dalfrà MG, et al. Reference intervals for hemoglobin A1c in pregnant women: data from an Italian multicenter study. Clin Chem. 2006; 52(6): 1138–1143.
  33. Jovanovic L, Knopp RH, Kim H, et al. Elevated pregnancy losses at high and low extremes of maternal glucose in early normal and diabetic pregnancy: evidence for a protective adaptation in diabetes. Diabetes Care. 2005; 28(5): 1113–1117.
  34. Lambert K, Holt RIG. The use of insulin analogues in pregnancy. Diabetes Obes Metab. 2013; 15(10): 888–900.
  35. Farrar D, Tuffnell DJ, West J, et al. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev. 2016(6): CD005542.
  36. Wender-Ozegowska E, Zawiejska A, Ozegowska K, et al. Multiple daily injections of insulin versus continuous subcutaneous insulin infusion for pregnant women with type 1 diabetes. Aust N Z J Obstet Gynaecol. 2013; 53(2): 130–135.
  37. Murphy HR, Rayman G, Lewis K, et al. Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial. BMJ. 2008; 337: a1680.
  38. Yogev Y, Ben-Haroush A, Chen R, et al. Continuous glucose monitoring for treatment adjustment in diabetic pregnancies--a pilot study. Diabet Med. 2003; 20(7): 558–562.
  39. Weight Gain During Pregnancy. 2009.
  40. Rizzo TA, Dooley SL, Metzger BE, et al. Prenatal and perinatal influences on long-term psychomotor development in offspring of diabetic mothers. Am J Obstet Gynecol. 1995; 173(6): 1753–1758.
  41. Nielsen LR, Müller C, Damm P, et al. Reduced prevalence of early preterm delivery in women with Type 1 diabetes and microalbuminuria--possible effect of early antihypertensive treatment during pregnancy. Diabet Med. 2006; 23(4): 426–431.
  42. Carr DB, Koontz GL, Gardella C, et al. Diabetic nephropathy in pregnancy: suboptimal hypertensive control associated with preterm delivery. Am J Hypertens. 2006; 19(5): 513–519.
  43. Abalos E, Duley L, Steyn DW, et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2007(1): CD002252.
  44. Lausman A, Kingdom J, Lausman A, et al. MATERNAL FETAL MEDICINE COMMITTEE. Screening, diagnosis, and management of intrauterine growth restriction. J Obstet Gynaecol Can. 2012; 34(1): 17–28.
  45. Vannevel V, Claes K, Baud D, et al. ACOG Committee on Practice Bulletins--Obstetrics, ACOG Committee on Obstetric Practice. Pregnancy outcome in 303 cases with severe preeclampsia. Obstet Gynecol. 1984; 64(3): 319–325.
  46. August P. Hypertensive Disorders in Pregnancy. Medical Complications During Pregnancy. 2004: 43–67.
  47. WHO. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. ; 2011.
  48. Rozporządzenie Ministra Zdrowia z dnia 9 listopada 2015 r. w sprawie standardów postępowania medycznego przy udzielaniu świadczeń zdrowotnych w dziedzinie położnictwa i ginekologii z zakresu okołoporodowej opieki położniczo-ginekologicznej, sprawowanej nad kobietą w okresie ciąży, porodu, połogu, w przypadkach występowania określonych powikłań oraz opieki nad kobietą w sytuacji niepowodzeń położniczych. ; 2015.
  49. American Diabetes Association. 13. Management of Diabetes in Pregnancy. Diabetes Care. 2017; 40(Suppl 1): S114–S119.
  50. Metzger BE, Gabbe SG, Persson B, et al. International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010; 33(3): 676–682.
  51. Webber J, Charlton M, Johns N. Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period (NG3). British Journal of Diabetes. 2015; 15(3): 107.
  52. Escobar-Morreale HF, Roldán-Martín MB. Type 1 Diabetes and Polycystic Ovary Syndrome: Systematic Review and Meta-analysis. Diabetes Care. 2016; 39(4): 639–648.
  53. ekspertów z. Polish Gynecological Society – Ultrasound Section Guidelines on ultrasound screening in uncomplicated pregnancy – 2015. Polish Gynaecology. 2015; 86(7): 551–558.
  54. Gutaj P, Wender-Ozegowska E. Diagnosis and Management of IUGR in Pregnancy Complicated by Type 1 Diabetes Mellitus. Curr Diab Rep. 2016; 16(5): 39.
  55. Nesbitt TS, Gilbert WM, Herrchen B. Shoulder dystocia and associated risk factors with macrosomic infants born in California. Am J Obstet Gynecol. 1998; 179(2): 476–480.
  56. Dildy GA, Clark SL. Shoulder dystocia: risk identification. Clin Obstet Gynecol. 2000; 43(2): 265–282.
  57. Acker DB, Sachs BP, Friedman EA. Risk factors for shoulder dystocia. Obstet Gynecol. 1985; 66(6): 762–768.
  58. Sandmire HF, O'Halloin TJ. Shoulder dystocia: its incidence and associated risk factors. Int J Gynaecol Obstet. 1988; 26(1): 65–73.
  59. Boulet SL, Alexander GR, Salihu HM, et al. Macrosomic births in the united states: determinants, outcomes, and proposed grades of risk. Am J Obstet Gynecol. 2003; 188(5): 1372–1378.
  60. Zhang X, Decker A, Platt RW, et al. How big is too big? The perinatal consequences of fetal macrosomia. Am J Obstet Gynecol. 2008; 198(5): 517.e1–517.e6.
  61. Øverland EA, Vatten LJ, Eskild A. Pregnancy week at delivery and the risk of shoulder dystocia: a population study of 2,014,956 deliveries. BJOG. 2014; 121(1): 34–41.
  62. Bomba-Opoń D, Drews K, Huras H, et al. Polish Gynecological Society Recommendations for Labor Induction. Ginekol Pol. 2017; 88(4): 224–234.
  63. Glueck CJ, Salehi M, Sieve L, et al. Growth, motor, and social development in breast- and formula-fed infants of metformin-treated women with polycystic ovary syndrome. J Pediatr. 2006; 148(5): 628–632.

Ważne: serwis wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: